Opinion

Video

Financial Considerations Influencing Treatment Strategies in PNH Treatment Pathway

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Jamie L. Koprivnikar, MD

The panelists provide their final thoughts, highlighting financial considerations in PNH treatment.

Video content above is prompted by the following question:

  • How do financial considerations influence your treatment decision-making process?
Related Videos
Fred Locke, MD, Moffitt Cancer Center and Research Institute
5 experts in this video
5 experts in this video
Pieter Sonneveld, MD, PhD
Mohit Narang, MD
Craig A. Portell, MD, UVA Health
Related Content
Among patients in the real-world setting, acalabrutinib was associated with reduced risks of AF or flutter and a reduced risk of hypertension. | Image credit: inthasone - stock.adobe.com
May 17th 2025

Lower Risk of Cardiovascular Events With Acalabrutinib vs Ibrutinib in CLL in Real-World Study

AJMC Contributor
The real-world data showed lower rates of atrial fibrillation and hypertension associated with the second-generation Bruton tyrosine kinase inhibitor among patients with chronic lymphocytic leukemia (CLL).
Managed Care Cast Presents: Challenges of Diagnosing and Managing PNH
July 16th 2024

Managed Care Cast Presents: Challenges of Diagnosing and Managing PNH

A trio of experts discuss the challenges of diagnosing and managing paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening disorder.
Patients with relapsed/refractory disease achieved an ORR of 63% in the phase 2 study. | Image Credit: Eleni - stock.adobe.com
May 16th 2025

Bexmarilimab Plus Azacitidine Meets ORR End Point in R/R Higher-Risk MDS

Courtney Flaherty
The addition of bexmarilimab to azacitidine elicited an ORR of 63% among patients with relapsed/refractory higher-risk myelodysplastic syndrome.
Podcast: This Week in Managed Care—Pushback on Proposed Payment Rules and Other Health News
September 15th 2018

Podcast: This Week in Managed Care—Pushback on Proposed Payment Rules and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
One of the key ways to manage thromboembolic event risk in PV is by controlling hematocrit, often by prescribing hydroxyurea. If patients develop resistance to the therapy, however, they face a higher risk of mortality. | Image credit: keetazalay - stock.adobe.com
May 6th 2025

Machine Learning Model Identifies Hydroxyurea Resistance Markers in PV

Jared Kaltwasser
Machine learning identifies key biomarkers predicting hydroxyurea resistance in polycythemia vera, enhancing early treatment strategies and patient outcomes.
While both are anti-CD20 antibodies, obinutuzumab is a glycoengineered type II CD20 antibody, and rituximab is a type I CD20 antibody, meaning a different mode of binding to CD20 antigen. | Image credit: Eleni - stock.adobe.com
May 1st 2025

Long-Term Data Show Favorable Survival Outcomes With G-Clb in Treatment-Naive CLL

AJMC Contributor
Participants in the CLL11 trial and a smaller group of patients followed after study completion showed improved overall survival with obinutuzumab and chlorambucil (G-Clb) compared with chemotherapy plus rituximab or chemotherapy alone for chronic lymphocytic leukemia (CLL).

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo